Evidence map›Paper›PMID 27612555›Full record

Trial reportAIDS research and human retroviruses

Increased Steady-State Memory B Cell Subsets Among High-Risk Participants in an HIV Vaccine Trial.

Michael C Keefer, Bo Zheng, Alexander F Rosenberg, James J Kobie

Open access · greenAbstract readClinical Trial, Phase II
In one paragraph

Trial report in AIDS research and human retroviruses. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Michael C Keefer1 Infectious Diseases Division, Department of Medicine, University of Rochester , Rochester, New York.
Bo Zheng1 Infectious Diseases Division, Department of Medicine, University of Rochester , Rochester, New York.
Alexander F Rosenberg2 Division of Allergy, Immunology, and Rheumatology, Department of Medicine, University of Rochester , Rochester, New York.
James J Kobie1 Infectious Diseases Division, Department of Medicine, University of Rochester , Rochester, New York.
University of Rochester · US

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
University of Rochester HIV/AIDS Clinical Trials Unit Administrative SupplementUM1AI069511 · NIAID · UNIVERSITY OF ROCHESTER · PI Paul R Bohjanen, MICHAEL C KEEFER · 2012 to 2026
$25.7M
Virology/Immunology CoreP30AI078498 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2008 to 2018
$14.6M
Units for HIV/AIDS Clinical Trials NetworksU01AI069511 · NIAID · UNIVERSITY OF ROCHESTER · PI KEEFER, MICHAEL C · 2007 to 2011
$12.0M
Targeting IgM Memory to Establish Protective B Cell Responses to HIVR01AI117787 · NIAID · UNIVERSITY OF ROCHESTER · PI KOBIE, JAMES J · 2015 to 2018
$2.7M
NIAID NIH HHS P30 AI078498NIAID NIH HHS R01 AI117787NIAID NIH HHS U01 AI069511NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI069511
6 · The paper itself

Abstract

The success of an HIV vaccine will require induction of a protective immune response in the most at-risk populations. The increased incidence of HIV infection in high-risk populations is assumed to be primarily the result of more frequent exposure to the virus or a greater inoculum of the virus; however, underlying variations in immune homeostasis may also contribute to HIV susceptibility and potentially impact vaccine responses and those required for protection. As an effective humoral immune response is likely to be a critical component of a protective HIV vaccine, we evaluated the steady-state phenotypic profile of peripheral blood B cells by flow cytometry from participants in the HIV Vaccine Trials Network (HVTN) 203 Phase 2a HIV vaccine trial considered to be at higher risk and lower risk for HIV acquisition. Overall, high-risk participants exhibited increased frequency of unswitched IgM memory and activated switched IgD

Indexed as

Immunologic MemoryAdolescentAdultAIDS VaccinesB-Lymphocyte SubsetsFemaleFlow CytometryHumansMaleMiddle AgedYoung AdultAIDS VaccinesB cellCXCR3HIVHIV in men who have sex with men (MSM)IgMvaccines

Identifiers

PMID27612555
PMCPMC5067846
OpenAlexW2537852299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.